The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.
Gary William Middleton
No relevant relationships to disclose
Juan W. Valle
No relevant relationships to disclose
Jonathan Wadsley
No relevant relationships to disclose
David Propper
No relevant relationships to disclose
Fareeda Y. Coxon
No relevant relationships to disclose
Paul J. Ross
No relevant relationships to disclose
Srinivasan Madhusudan
No relevant relationships to disclose
Tom Roques
No relevant relationships to disclose
David Cunningham
No relevant relationships to disclose
Philippa Corrie
No relevant relationships to disclose
William Greenhalf
No relevant relationships to disclose
Victoria Shaw
No relevant relationships to disclose
Trevor F. Cox
No relevant relationships to disclose
Paul Silcocks
No relevant relationships to disclose
Gemma Nanson
No relevant relationships to disclose
John P. Neoptolemos
No relevant relationships to disclose